47 PatilN.WalshP.CarrabreK.HolmbergE
Svetlana Mojsov, a researcher at Rockefeller University whose work has been important in the characterization of GLP-1 and clarification of its role in glucose metabolism, explained in an interview with PNAS this September, Once we solve obesity, I think a lot of other disorders will be taken care of As for all the other pathophysiological states in which GLP-1-based drugs appear to be beneficial, I think it may have something to do with the drugs central role in regulating glucose metabolism. But lowering glucose isnt GLP-1s only job, though as Mojsov said, the relationship with glucose metabolism may be a crucial central part in the many related conditions it seems to treat

Moreover, the relatively small change in NOE intensity observed for the CTAB/SNAC -a/c NOE crosspeak also indicates that aggregation size effects on the correlation times are very likely small compared to the changes in NOEs caused by SNAC aggregation in our system, consistent with the fact that the large CTAB/SNAC aggregates (Fig
[DOI] [PMC free article] [PubMed] [Google Scholar] 142.Aghamohammadi V., Gargari B.P., Aliasgharzadeh A